ArticleFrontiers in oncology2024

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.

Shereen Elazzazy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.